Alembic Pharma Q3 Results: Consolidated net profit declines 23% to ₹138 crore, stock down 5%

Alembic Pharmaceuticals reported a 23.29% decline in Q3 FY25 net profit at ₹138.42 crore, despite a 3.81% revenue increase to ₹1,692.74 crore. The stock dropped over 5% post-earnings announcement.